Navin Fluorine growth visibility builds on R32, CDMO and Advanced Materials

Investment View and Valuation

In its management-meet update dated 21 August 2026, PL Research retains an ACCUMULATE rating on Navin Fluorine International (NFIL) and raises the target price to Rs 8,812 from Rs 8,377. The broker views NFIL as well positioned for a strong multi-year growth trajectory, supported by demand across its businesses and several expansion-led growth levers.

PL Research expects revenue, EBITDA and PAT CAGRs of 22 per cent, 24 per cent and 29 per cent, respectively, over FY26 to FY28E. The target price is based on a valuation of 41 times FY28E EPS.

Growth Outlook and Management Guidance

Management reiterated its earlier guidance for around 25 per cent revenue CAGR through FY30. The principal near-to-medium-term growth driver is the expansion of R32 capacity, which management expects to contribute around 20 to 25 per cent of revenue by FY28. Around 30 to 40 per cent of the expanded R32 capacity has already been contracted.

Management remains confident that the USD100 million CDMO revenue objective for FY27 is on track. NFIL is undertaking Phase 2 of the cGMP4 expansion, along with related infrastructure capital expenditure for cGMP5 and cGMP6. Darolutamide is expected to remain an important CDMO growth driver, aided by rising Nubeqa demand in newer geographies and additional approvals.

Advanced Materials: Longer-Term Opportunity

Advanced Materials is identified as the key longer-term opportunity for NFIL. The portfolio comprises around 19 to 20 fluorination-based products with laboratory and kilo-lab approvals, serving niche applications in semiconductors, defence, electronics and data centres.

NFIL is developing a facility involving investment of roughly Rs 900 million at the adoption stage, with the objective of securing commercial-scale customer approvals. Management expects Advanced Materials to become comparable in scale with the current CDMO business by FY30 and to contribute around 10 to 15 per cent of expanded revenue.

Although asset turns are expected to be lower, management expects the niche product portfolio to support high margins. Technology development is fully in-house and supported by a dedicated research and development team.

Capital Expenditure and HFO Opportunity

NFIL plans capital expenditure of around Rs 7,000 million in FY27. Annual capital expenditure is expected to be around Rs 7,000 million to Rs 10,000 million over the following two to three years, across R32, CDMO and Advanced Materials.

HFO represents a more distant opportunity. NFIL expects to enter the HFO market after FY29, as demand is expected to rise meaningfully after CY32. The USD410 million HFO contract over seven years remains unchanged.

Financial Estimates

FY27E and FY28E sales and EBITDA estimates are unchanged. However, EPS estimates have been reduced by 1.6 per cent and 2.5 per cent, respectively, to Rs 178.6 and Rs 214.9. PL Research values NFIL at 41 times FY28E EPS to derive the target price of Rs 8,812.

Key Execution Considerations

The report does not provide a separate risk section. Its growth outlook is linked to the execution of R32, CDMO and Advanced Materials capacity plans, customer approvals and the ramp-up of contracted capacity.